NxStage Medical (NSDQ:NXTM) today released the results from a study of its Nx2me connected health remote patient management system for patients using home hemodialysis, touting a 29% reduction in technique failure of conversion to in-center hemodialysis by 29%.
Results from the study were published in the journal Hemodialysis International, the Lawrence, Mass.-based company said.
Data came from a total 606 Nx2me users including both patients on home hemodialysis with the NxStage System One and new home hemodialysis patients, NxStage said.
Technique failure was reduced by 34% For patients who began to use the Nx2me within 3 months of starting home hemodialysis relative to matched controls. Results also indicated that patients who began using the Nx2me during home hemodialysis training were 61% more likely to complete training in 7 fewer days compared to controls.
The Nx2me connected health operates through the Nx2me app, which uses tablets, cloud computing and wireless communications to collect home hemodialysis data in addition to patient information like blood pressure and weight. Patients can review, confirm, and transmit this data to their centers after each treatment, the company said.
“Nx2me provides the tools to support and proactively engage with patients. Nx2me enhances dialysis care for both patients and center staff, and the performance data continue to demonstrate improved training graduation and patient retention, which both help to grow home hemodialysis,” NxStage clinical epidemiologist & statistician Eric Weinhandl said in a press release.
In October, Fresenius Medical Care (NYSE:FMS; ETR:FRE) and NxStage Medical (NSDQ:NXTM) said they have received a request from the US Federal Trade Commission asking for more information on Fresenius’ $2 billion acquisition of NxStage.